HAEMONETICS CORP
Financial highlights
| Metric | FY 03/28/26 | FY 03/29/25 | FY 03/30/24 | FY 04/01/23 | FY 04/02/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3B | $1.4B | $1.3B | $1.2B | $993.2M |
| Cost of revenue | $546.4M | $611.9M | $617.5M | $553.6M | $487.7M |
| Gross profit | $787.6M | $749.0M | $691.5M | $615.1M | $505.5M |
| Selling, general & administrative | $442.4M | $436.8M | $429.8M | $376.7M | $340.1M |
| Research and development | $59.8M | $62.7M | $54.4M | $50.1M | $46.8M |
| Operating expenses | $630.9M | $527.1M | $526.7M | $459.1M | $424.8M |
| Operating income | $156.7M | $221.8M | $164.9M | $156.0M | $80.8M |
| Pretax income | $128.0M | $212.1M | $151.9M | $141.4M | $63.6M |
| Income tax expense | $30.7M | $44.4M | $34.3M | $26.0M | $20.3M |
| Net income | $97.3M | $167.7M | $117.6M | $115.4M | $43.4M |
| Balance Sheet | |||||
| Cash and equivalents | $245.4M | $306.8M | $178.8M | $284.5M | $259.5M |
| Current assets | $834.9M | $935.0M | $768.9M | $769.7M | $756.0M |
| Total assets | $2.4B | $2.5B | $2.2B | $1.9B | $1.9B |
| Current liabilities | $282.6M | $578.1M | $300.4M | $251.8M | $442.3M |
| Total debt | $1.2B | $1.2B | — | — | — |
| Stockholders' equity | $796.3M | $820.8M | $960.0M | $818.0M | $749.4M |
| Cash Flow Statement | |||||
| Cash from operations | $293.2M | $181.7M | $181.8M | $273.1M | $172.3M |
| Depreciation and amortization | $61.2M | $60.0M | $55.8M | $51.2M | $44.4M |
| Stock-based compensation | $33.8M | $29.6M | $28.3M | $25.6M | $24.4M |
| Capital expenditure | $32.8M | $39.3M | $38.1M | $191.3M | $96.5M |
| Free cash flow | $260.4M | $142.4M | $143.6M | $81.7M | $75.8M |
| Share repurchases | $175.0M | $225.0M | $0 | $75.0M | $0 |
| Impairments | $86.5M | $2.4M | $10.4M | $607,000 | $8.0M |
Shares outstanding 46.5M · Free float 98.0%
Annual filing data through FY ended March 28, 2026; float as of July 8, 2026.